Is BioAffinity Technologies, Stock a Good Investment?
BioAffinity Technologies, Investment Advice | BIAF |
- Examine BioAffinity Technologies,'s financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research BioAffinity Technologies,'s leadership team and their track record. Good management can help BioAffinity Technologies, navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact BioAffinity Technologies,'s business and its evolving consumer preferences.
- Compare BioAffinity Technologies,'s performance and market position to its competitors. Analyze how BioAffinity Technologies, is positioned in terms of product offerings, innovation, and market share.
- Check if BioAffinity Technologies, pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about BioAffinity Technologies,'s stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in bioAffinity Technologies, stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if bioAffinity Technologies, is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine BioAffinity Technologies, Stock
Researching BioAffinity Technologies,'s stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 30.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.91. bioAffinity Technologies, had not issued any dividends in recent years.
To determine if BioAffinity Technologies, is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding BioAffinity Technologies,'s research are outlined below:
| BioAffinity Technologies, generated a negative expected return over the last 90 days | |
| BioAffinity Technologies, has high historical volatility and very poor performance | |
| BioAffinity Technologies, may become a speculative penny stock | |
| BioAffinity Technologies, has a very high chance of going through financial distress in the upcoming years | |
| bioAffinity Technologies, currently holds 1.58 M in liabilities. bioAffinity Technologies, has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about BioAffinity Technologies,'s use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 2.53 M. Net Loss for the year was (7.94 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| bioAffinity Technologies, currently holds about 214.4 K in cash with (6.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08. | |
| Roughly 30.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: bioAffinity Technologies stock hits 52-week low at 1.21 - Investing.com |
BioAffinity Technologies, Quarterly Liabilities And Stockholders Equity |
|
BioAffinity Technologies, uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in bioAffinity Technologies,. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to BioAffinity Technologies,'s previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Earnings surprises can significantly impact BioAffinity Technologies,'s stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises BioAffinity Technologies,'s investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-14 | 2024-06-30 | -0.17 | -0.19 | -0.02 | 11 | ||
2023-05-15 | 2023-03-31 | -0.21 | -0.18 | 0.03 | 14 | ||
2024-05-15 | 2024-03-31 | -0.2 | -0.2567 | -0.0567 | 28 | ||
2023-08-14 | 2023-06-30 | -0.13 | -0.2 | -0.07 | 53 | ||
2023-11-14 | 2023-09-30 | -0.15 | -0.26 | -0.11 | 73 |
Know BioAffinity Technologies,'s Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as BioAffinity Technologies, is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading bioAffinity Technologies, backward and forwards among themselves. BioAffinity Technologies,'s institutional investor refers to the entity that pools money to purchase BioAffinity Technologies,'s securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Cypress Capital, Llc | 2024-06-30 | 200 | Bank Of America Corp | 2024-06-30 | 65.0 | Qube Research & Technologies | 2024-06-30 | 38.0 | Jpmorgan Chase & Co | 2024-06-30 | 18.0 | Ground Swell Capital, Llc | 2024-09-30 | 0.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Renaissance Technologies Corp | 2024-09-30 | 0.0 | Vanguard Group Inc | 2024-09-30 | 260.9 K | Geode Capital Management, Llc | 2024-06-30 | 69.6 K | Captrust Financial Advisors | 2024-06-30 | 27.9 K | Sheaff Brock Investment Advisors, Llc | 2024-09-30 | 20 K |
BioAffinity Technologies,'s market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 19.81 M.Market Cap |
|
BioAffinity Technologies,'s profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.33) | (1.39) | |
| Return On Capital Employed | (1.33) | (1.27) | |
| Return On Assets | (0.97) | (1.01) | |
| Return On Equity | (1.63) | (1.55) |
Determining BioAffinity Technologies,'s profitability involves analyzing its financial statements and using various financial metrics to determine if BioAffinity Technologies, is a good buy. For example, gross profit margin measures BioAffinity Technologies,'s profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of BioAffinity Technologies,'s profitability and make more informed investment decisions.
Evaluate BioAffinity Technologies,'s management efficiency
bioAffinity Technologies, has return on total asset (ROA) of (0.6978) % which means that it has lost $0.6978 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5152) %, meaning that it created substantial loss on money invested by shareholders. BioAffinity Technologies,'s management efficiency ratios could be used to measure how well BioAffinity Technologies, manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -1.39. The BioAffinity Technologies,'s current Return On Capital Employed is estimated to increase to -1.27. At this time, BioAffinity Technologies,'s Other Assets are most likely to decrease significantly in the upcoming years. The BioAffinity Technologies,'s current Fixed Asset Turnover is estimated to increase to 1.33, while Non Currrent Assets Other are projected to decrease to roughly 10 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.56 | 0.58 | |
| Tangible Book Value Per Share | 0.30 | 0.31 | |
| Enterprise Value Over EBITDA | (1.52) | (1.60) | |
| Price Book Value Ratio | 2.65 | 2.78 | |
| Enterprise Value Multiple | (1.52) | (1.60) | |
| Price Fair Value | 2.65 | 2.78 | |
| Enterprise Value | 11.6 M | 11 M |
Evaluating the management effectiveness of BioAffinity Technologies, allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The BioAffinity Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Beta 3.124 |
Basic technical analysis of BioAffinity Stock
As of the 22nd of November, BioAffinity Technologies, shows the Risk Adjusted Performance of (0.02), coefficient of variation of (2,830), and Standard Deviation of 7.08. bioAffinity Technologies, technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm bioAffinity Technologies, treynor ratio, as well as the relationship between the value at risk and skewness to decide if bioAffinity Technologies, is priced correctly, providing market reflects its regular price of 1.25 per share. Given that BioAffinity Technologies, is a hitting penny stock territory we recommend to closely look at its jensen alpha.BioAffinity Technologies,'s insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BioAffinity Technologies, insiders, such as employees or executives, is commonly permitted as long as it does not rely on BioAffinity Technologies,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases BioAffinity Technologies, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Understand BioAffinity Technologies,'s technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing BioAffinity Technologies,'s various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.28) | |||
| Mean Deviation | 4.28 | |||
| Coefficient Of Variation | (2,830) | |||
| Standard Deviation | 7.08 | |||
| Variance | 50.13 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.35) | |||
| Total Risk Alpha | (1.18) | |||
| Treynor Ratio | (0.29) | |||
| Maximum Drawdown | 61.86 | |||
| Value At Risk | (7.33) | |||
| Potential Upside | 10.1 | |||
| Skewness | (0.50) | |||
| Kurtosis | 10.38 |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.28) | |||
| Mean Deviation | 4.28 | |||
| Coefficient Of Variation | (2,830) | |||
| Standard Deviation | 7.08 | |||
| Variance | 50.13 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.35) | |||
| Total Risk Alpha | (1.18) | |||
| Treynor Ratio | (0.29) | |||
| Maximum Drawdown | 61.86 | |||
| Value At Risk | (7.33) | |||
| Potential Upside | 10.1 | |||
| Skewness | (0.50) | |||
| Kurtosis | 10.38 |
Consider BioAffinity Technologies,'s intraday indicators
BioAffinity Technologies, intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of BioAffinity Technologies, stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
BioAffinity Technologies, time-series forecasting models is one of many BioAffinity Technologies,'s stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary BioAffinity Technologies,'s historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
BioAffinity Stock media impact
Far too much social signal, news, headlines, and media speculation about BioAffinity Technologies, that are available to investors today. That information is available publicly through BioAffinity media outlets and privately through word of mouth or via BioAffinity internal channels. However, regardless of the origin, that massive amount of BioAffinity data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of BioAffinity Technologies, news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of BioAffinity Technologies, relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to BioAffinity Technologies,'s headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive BioAffinity Technologies, alpha.
BioAffinity Technologies, Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards BioAffinity Technologies, can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
BioAffinity Technologies, Corporate Management
| Timothy JD | Secretary VP | Profile | |
| Dallas Coleman | National Sales | Profile | |
| William Bauta | Senior Therapeutics | Profile | |
| Maria JD | President, Founder | Profile | |
| Xavier MS | VP Operations | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in bioAffinity Technologies,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in BioAffinity Stock please use our How to Invest in BioAffinity Technologies, guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioAffinity Technologies,. If investors know BioAffinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioAffinity Technologies, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.91) | Revenue Per Share 0.744 | Quarterly Revenue Growth 120.474 | Return On Assets (0.70) | Return On Equity (1.52) |
The market value of bioAffinity Technologies, is measured differently than its book value, which is the value of BioAffinity that is recorded on the company's balance sheet. Investors also form their own opinion of BioAffinity Technologies,'s value that differs from its market value or its book value, called intrinsic value, which is BioAffinity Technologies,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioAffinity Technologies,'s market value can be influenced by many factors that don't directly affect BioAffinity Technologies,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between BioAffinity Technologies,'s value and its price, as these two are different measures arrived at by various means. Investors typically determine if BioAffinity Technologies, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioAffinity Technologies,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.